Context Therapeutics (NASDAQ:CNTX - Get Free Report) had its price objective dropped by equities researchers at HC Wainwright from $5.00 to $4.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price points to a potential upside of 455.71% from the company's current price.
A number of other research analysts have also recently weighed in on CNTX. D. Boral Capital restated a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a research report on Thursday. Piper Sandler restated an "overweight" rating and set a $4.00 target price (down previously from $4.50) on shares of Context Therapeutics in a research report on Thursday, June 26th. Finally, William Blair restated an "outperform" rating on shares of Context Therapeutics in a research report on Tuesday, April 29th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $5.25.
Check Out Our Latest Research Report on Context Therapeutics
Context Therapeutics Price Performance
Shares of CNTX stock traded up $0.02 during midday trading on Thursday, reaching $0.72. 116,001 shares of the company traded hands, compared to its average volume of 199,944. The firm's 50 day simple moving average is $0.69 and its two-hundred day simple moving average is $0.75. The firm has a market cap of $64.57 million, a PE ratio of -2.00 and a beta of 1.89. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.75.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). As a group, research analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.
Insider Transactions at Context Therapeutics
In other news, CEO Martin A. Lehr bought 100,000 shares of Context Therapeutics stock in a transaction on Monday, June 9th. The shares were bought at an average cost of $0.70 per share, for a total transaction of $70,000.00. Following the acquisition, the chief executive officer owned 920,190 shares in the company, valued at approximately $644,133. This trade represents a 12.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of Context Therapeutics stock in a transaction on Friday, June 6th. The stock was purchased at an average price of $0.64 per share, for a total transaction of $25,606.40. Following the completion of the acquisition, the chief financial officer owned 80,010 shares in the company, valued at $51,206.40. This represents a 100.03% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 160,010 shares of company stock valued at $107,206. 2.80% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of Context Therapeutics in the fourth quarter valued at $29,000. Citadel Advisors LLC purchased a new stake in Context Therapeutics in the 4th quarter valued at about $31,000. Shay Capital LLC purchased a new stake in Context Therapeutics in the 4th quarter valued at about $52,000. Landscape Capital Management L.L.C. acquired a new position in shares of Context Therapeutics during the 4th quarter valued at about $94,000. Finally, Walleye Capital LLC lifted its holdings in shares of Context Therapeutics by 51.7% during the 4th quarter. Walleye Capital LLC now owns 166,306 shares of the company's stock worth $175,000 after acquiring an additional 56,651 shares during the period. 14.03% of the stock is currently owned by hedge funds and other institutional investors.
About Context Therapeutics
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Featured Articles
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
